

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application:

1. (Currently Amended) A transgenic mouse ~~non-human mammal or a portion thereof~~, wherein ~~[[an]]~~ a human α -synuclein gene with a C-terminal deletion linked to a tyrosine hydroxylase promoter is introduced ~~and the gene is expressed in the neurons, and the number of dopamine-producing neurons in the substantia nigra is significantly decreased as compared with that of a wild-type animal.~~

2. (Cancelled)

3. (Currently Amended) The transgenic mouse ~~non-human mammal or a portion thereof~~ according to claim 1, wherein the α -synuclein gene ~~is a variant of a wild-type human α -synuclein gene in a manner that substitutes a~~ has substitution of a Thr residue for an Ala residue at amino acid residue 53 ~~in an amino acid sequence encoded by the wild-type human α -synuclein gene.~~

4.-7. (Cancelled)

8. (Currently Amended) The transgenic mouse ~~non-human mammal or a portion thereof~~ according to claim 1, wherein the transgenic mouse has at least 85% decrease in[[an]] intracerebral dopamine level at an early age of at least 5 days ~~is decreased to 85% or less as compared with that of~~ to a wild-type mouse animal.

9. (Currently Amended) The transgenic mouse ~~non-human mammal or a portion thereof~~ according to claim 1, wherein the transgenic mouse has at least a tyrosine hydroxylase expression level is decreased to 80% decrease in intracerebral tyrosine hydroxylase level ~~or less as compared with that of~~ to a wild-type mouse animal.

10. (Currently Amended) The transgenic mouse ~~non-human mammal or a portion thereof~~

according to claim 1, wherein the transgenic mouse has at least a spontaneous locomotor activity is decreased to 60% decrease in spontaneous locomotor activity or less as compared with that of to a wild-type mouse animal.

11.-13. (Cancelled)

14. (Withdrawn – Currently Amended) A substance obtained by [[the]] performing a method for screening a substance having dopamine-like action, wherein the transgenic mouse according to claim 1 is used screening method according to claim 12.

15. (Withdrawn – Currently Amended) A therapeutic agent or preventive agent for Parkinson's disease which comprises a substance obtained by the screening method according to ~~claim 12~~ claim 14, as an active ingredient.

16. (New) The transgenic mouse according to claim 1, wherein the α -synuclein gene is expressed in the neurons, and the transgenic mouse has at least 50% decrease in the number of dopamine-producing neurons in the substantia nigra as compared to a wild type mouse.